Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24701914 | 0.91 | ALDH1A1 (0.33) | KDM4E | |
| SCHEMBL5002480 | 0.88 | MEN1 (0.41) | MEN1POLBKMT2AKDM4ETSHR | |
| SCHEMBL25567922 | 0.83 | MEN1 (0.31) | MEN1POLBKMT2AKDM4ETSHR | |
| SCHEMBL12120256 | 0.80 | KDM4E (0.33) | KDM4E | |
| SCHEMBL20118757 | 0.79 | KDM4E (0.42) | MEN1KMT2AKDM4ETSHR | |
| SCHEMBL25565757 | 0.77 | KDM4E (0.38) | KDM4E | |
| SCHEMBL26711220 | 0.77 | MEN1 (0.31) | MEN1POLBKMT2A | |
| SCHEMBL29339694 | 0.77 | BLM (0.46) | KMT2AKDM4ETSHR | |
| SCHEMBL22137686 | 0.77 | HTT (0.33) | TSHR | |
| SCHEMBL12448059 | 0.76 | MEN1 (0.45) | MEN1POLBKMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340146-A1 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | PIK3CA, PIK3CD, PIK3R5 | MEN1 1606/4885POLB 2123/4885KMT2A 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.